An opportunity for investors

Ulf Björklund, Chairman of the Board,
talks about his role in the company (in Swedish).
Einar Pontén, CEO, presents Lipum and futured plans.

Partnering for development

Our scientists have a ongoing collaboration with the SciLifeLab in Uppsala and Lipum is actively seeking partners for faster and competent development. We welcome service providers to contact us if you feel you can contribute. We are also very interested in establishing strategic partnerships for different stages of drug development.

An opportunity for investors

A novel mode of action, less adverse effects on the immune system, and the potential for an orphan drug designation are factors we beleive makes Lipum an attractive investment.

The company has its roots in the academic environment and basic preclinical research has mainly been funded by academic grants. More recently the company has received soft funding from Novo Seeds, Innovationsbron and Umeå Biotech Incubator.

In June 2016 Almi Invest AB became shareholder by investing 2,5 MSEK in Lipum AB. Since then Lipum has also received funding from the European Union’s Horizon 2020 research and innovation programme SME Instrument phase 1 under grant agreement No 744248 and SME Instrument phase 2 grant agreement No 829741.